



Role of Microbiota in Colonic Inflammation and Colon Cancer

Guest Editor:

Dr. Jianan Zhang

Cutaneous Biology Research
Center, Mass General Hospital,
Harvard Medical School, Boston,
MA, USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

The microbiota, a biological ecosystem that communicates strongly with the host, has been widely identified as an emerging factor of inflammation, which further impacts cancer. Colon cancer, one of the most common malignancies worldwide, is frequently associated with dramatic alterations in the microbial composition of the tumor. Although the effects of several specific bacterial strains on colon inflammation and cancer have been reported, how the microbiota communicates with the colon to promote inflammatory responses is still poorly understood. In this Special Issue, we focus on the role of the microbiota in colon inflammation and cancer, especially its detailed molecular mechanism and clinical treatment, aiming to develop management strategies for colon-related diseases through targeting the microbiota.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI